Medicine
Symvess 420 mm implant
Symvess 420 mm implant is a prescription medicine containing Acellular tissue engineered vessel for intravascular use, marketed by Humacyte Global, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. A FreezeAlert temperature indicator is attached to the exterior…
Key facts
- Active ingredient (INN)
- Acellular tissue engineered vessel
- Brand
- Symvess
- Strength
- 420 mm
- Dosage form
- Implant
- Route
- Intravascular
- Packs
- 1 box
- Marketing authorisation holder
- Humacyte Global
- Manufacturer
- Humacyte Global
- Origin register
- US FDA, United States
- Storage
- Do not freeze. A FreezeAlert temperature indicator is attached to the exterior of each thermoformed tray that contains a SYMVESS. Prior to preparing SYMVESS for a procedure, check the FreezeAlert indicator. A check mark indicates SYMVESS has not been exposed to freezing temperatures and can be used. Store SYMVESS at 2ºC to 8ºC (36ºF to 46ºF).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 December 2024
- Identifiers
- RxCUI 2700346, 2700352DailyMed set ID 15e9e29f-5aa6-4fc6-b0fe-a48cd1473418NDC 83564-110Application BLA125812
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 box in 1 bag / 1 implant in 1 box | 83564-110-00 | Humacyte Global | 19 December 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Acellular tissue engineered vessel is a prescription medicine. It is available as implants for intravascular use. MedsAcross supplies Acellular tissue engineered vessel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Acellular tissue engineered vesselFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Symvess prescribing information (Humacyte Global) · U.S. National Library of Medicine, DailyMed
Need Symvess 420 mm implant for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.